Correlation Between Powerchip Semiconductor and Synmosa Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Powerchip Semiconductor and Synmosa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Powerchip Semiconductor and Synmosa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Powerchip Semiconductor Manufacturing and Synmosa Biopharma, you can compare the effects of market volatilities on Powerchip Semiconductor and Synmosa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Powerchip Semiconductor with a short position of Synmosa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Powerchip Semiconductor and Synmosa Biopharma.

Diversification Opportunities for Powerchip Semiconductor and Synmosa Biopharma

0.88
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Powerchip and Synmosa is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Powerchip Semiconductor Manufa and Synmosa Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Synmosa Biopharma and Powerchip Semiconductor is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Powerchip Semiconductor Manufacturing are associated (or correlated) with Synmosa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Synmosa Biopharma has no effect on the direction of Powerchip Semiconductor i.e., Powerchip Semiconductor and Synmosa Biopharma go up and down completely randomly.

Pair Corralation between Powerchip Semiconductor and Synmosa Biopharma

Assuming the 90 days trading horizon Powerchip Semiconductor Manufacturing is expected to under-perform the Synmosa Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Powerchip Semiconductor Manufacturing is 28.84 times less risky than Synmosa Biopharma. The stock trades about -0.08 of its potential returns per unit of risk. The Synmosa Biopharma is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  3,520  in Synmosa Biopharma on September 12, 2024 and sell it today you would lose (150.00) from holding Synmosa Biopharma or give up 4.26% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Powerchip Semiconductor Manufa  vs.  Synmosa Biopharma

 Performance 
       Timeline  
Powerchip Semiconductor 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Powerchip Semiconductor Manufacturing has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Synmosa Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Synmosa Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Powerchip Semiconductor and Synmosa Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Powerchip Semiconductor and Synmosa Biopharma

The main advantage of trading using opposite Powerchip Semiconductor and Synmosa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Powerchip Semiconductor position performs unexpectedly, Synmosa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will offset losses from the drop in Synmosa Biopharma's long position.
The idea behind Powerchip Semiconductor Manufacturing and Synmosa Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation